HPV 18, Cervix

Laboratory assay overview

Diagnose primary or metastatic neoplasm; detect Chlamydia trachomatis and Neisseria gonorrhoeae . The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 without further specific differentiation.

Laboratory assay overview

Diagnose primary or metastatic neoplasm; detect Chlamydia trachomatis and Neisseria gonorrhoeae. The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types 31,33,35,39,45,51,52,56,58,59,66, and 68, without further specific differentiation.

Laboratory assay overview

Diagnose primary or metastatic neoplasm; detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis . The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 without further specific differentiation.

Laboratory assay overview

Diagnose primary or metastatic neoplasm; detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types 31,33,35,39,45,51,52,56,58,59,66, and 68, without further specific differentiation.

Laboratory assay overview

Diagnose primary or metastatic neoplasm. The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 without further specific differentiation.

Laboratory assay overview

Diagnose primary or metastatic neoplasm. The HPV test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types 31,33,35,39,45,51,52,56,58,59,66, and 68, without further specific differentiation.

Laboratory assay overview

This test is indicated for use in cervical cancer screening algorithms as per professional medical guidelines to assess the risk for cervical precancer and cancer in patients 25 years of age and older.

Laboratory assay overview

This test specifically identifies types HPV16 and HPV18 while concurrently detecting the rest of the high-risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 without further specific differentiation.

Laboratory assay overview

This test is used for the detection of high-risk Human Papillomavirus in clinician-collected cervical samples and can be used as part of an HPV primary screening algorithm. The test detects high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, which are reported out as HPV 16, HPV 18, and other high-risk HPV types which includes, but does not differentiate, the remaining 12 high-risk types. Interim guidance supports the use of an HPV primary screening algorithm, where high-risk HPV testing is used as a first line screen, in women ≥25 years of age [1]. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medial history, and other risk factors. Specimens collected in SurePath collection devices have not been validated for use in HPV primary screening algorithms. If utilizing HPV primary screening algorithms, specimens collected in ThinPrep collection devices are approved by the Food and Drug Administration (FDA). 1. Huh WK, Ault KA, Chelmow D, et al. Use of primary high- risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330-337. doi:10.1097/AOG.0000000000000669

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

Laboratory assay overview

Detection of HPV type 16 and types 18,45 in cervical specimens where high-risk HPV types have been detected.